OliX Moves Into Spotlight Amid Strong RNAi Interest, New Platform
Big Pharma Deals To Follow?
With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.
You may also be interested in...
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.